Why Was MDS Renamed? Does It Change Treatment for Patients?

In 2022, the World Health Organization (WHO) updated the name of myelodysplastic syndrome to myelodysplastic neoplasm to better reflect the disease’s biology ^[1]. However, this name change alone does not mean your disease is more severe, nor does it automatically change your prognosis, risk score, or treatment plan ^[2]. The abbreviation remains “MDS,” and many doctors and patients continue to use both terms interchangeably ^[1].

The Bottom Line
The terminology change alone does not change the biology of your MDS. However, applying updated classification rules might change your specific MDS subtype. It is important to ask your doctor whether your report reflects only new wording or an actual change in your diagnostic category or risk features.

Why the Name Change?

For decades, MDS was called a “syndrome” because the word describes a collection of clinical signs—namely, low blood counts (cytopenias) and abnormally shaped blood cells (dysplasia) ^[3]. However, researchers now know that MDS usually results from acquired genetic and chromosomal changes in the stem cells of your bone marrow ^[4]. These changes are acquired (meaning they develop over your lifetime, not passed down in families) and clonal (meaning the abnormal cells multiply from a single damaged cell) ^[4]. While some cases have no detectable abnormality on standard tests, most are driven by these acquired changes.

The word neoplasm means “new growth.” While some neoplasms are benign, MDS is classified as a malignant neoplasm—a type of blood cancer ^[1][2]. Unlike solid cancers, it usually does not form a tumor. The WHO made this terminology update to emphasize this malignant, clonal nature ^[1]. Acknowledging MDS as a form of blood cancer helps researchers, doctors, and regulatory agencies align on how to classify and treat it ^[4]. It is completely normal to feel alarmed by the words “malignant” or “cancer,” but remember that MDS ranges from lower to higher risk, and the label alone cannot determine your outlook.

Does the New Name Change My Treatment or Prognosis?

The shift in terminology alone does not alter your individual risk level or mean your condition has suddenly worsened ^[2][5].

However, there is an important difference between a name change and a diagnostic reclassification. When doctors apply the new 2022 WHO criteria, they might find that your specific subtype of MDS has changed based on new genetic categories ^[6]. If your diagnostic category or risk features actually change under the new rules, that could affect your treatment ^[6].

Your prognosis (the likely course of your disease) and treatment plan are based on the biological details of your MDS ^[5]. Doctors calculate your risk using specialized scoring systems, such as the Molecular International Prognostic Scoring System (IPSS-M) or the older IPSS-R ^[7]. These tools do not look at the name of the disease; instead, they estimate outcomes for groups of patients based on objective data ^[8]:

• The percentage of immature cells (blasts) in your bone marrow
• The severity of your low blood counts
• Chromosomal (cytogenetic) changes
• Specific acquired genetic mutations driving your disease (if molecular testing is available) ^[8][9]

Your treatment is based on your unique risk category, genetic subtype, symptoms, transfusion needs, transplant eligibility, and overall health—not the word “neoplasm” ^[5][10].

Different Classifications in the Lab

While the WHO updated its classification to “myelodysplastic neoplasms” in 2022, another expert group called the International Consensus Classification (ICC) also published updated guidelines around the same time ^[11]. The ICC generally retains the term “myelodysplastic syndromes.”

The two systems are very similar and both recognize the importance of genetic mutations, but they use slightly different cutoffs for certain subtypes ^[11]. Because of this, you might see “syndrome” on a report from a lab using the ICC guidelines, and “neoplasm” on a report from a lab using the WHO guidelines ^[6]. It is completely normal for clinicians to use both terms. If you are confused by the wording, ask your care team which classification system they use.